| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Collagen Cross-Linked N-Telopeptide (NTx), 24-Hour Urine : 36421
Test CodeUNT24Q or 36421
Alias/See Also
N-Telopeptide, NTx
CPT Codes
82523, 82570
Includes
Includes Creatinine.
Instructions
24-hour urine: Do not include first morning specimen; collect all subsequent voidings. The last sample collected should be the first morning specimen voided the following morning at the same time as the previous morning's first voiding. Keep refrigerated during collection.
Collect 24 hour urine. Do not use preservatives. Acidified specimen is not acceptable.
Collect 24 hour urine. Do not use preservatives. Acidified specimen is not acceptable.
Transport Container
Submit 2 mL (Min: 1 mL) of a well mixed 24 hour urine collection. No preservatives. Record volume on requisition and urine vial.
Transport Temperature
Refrigerated.
Specimen Stability
Ambient: 72 hours; Refrigerated: 5 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Received room temperature, Acidified specimen, Preserved specimen.
Methodology
Chemiluminescence
Setup Schedule
Sunday & Tuesday & Thursday
Report Available
1-4 days (From receipt at performing laboratory)
Limitations
Requires accurate 24-hour urine collection. Collagen Cross-Linked N-Telopeptide is affected by diurnal variation.
Reference Range
| Male 18-29 Years: 5-88 nM BCE/mM creat 30-39 Years: 7-51 nM BCE/mM creat 40-49 Years: 5-47 nM BCE/mM creat 50-60 Years: 6-43 nM BCE/mM creat Female Premenopausal: 5-79 nM BCE/mM creat Results are primarily used for monitoring the response to therapy. A value within the premenopausal reference range does not rule out osteoporosis nor the need for therapy. Creatinine, 24-Hour Urine < 3 years Not established 3-8 Years 0.10-0.80 g/24 h 9-12 Years 0.20-1.40 g/24 h 13-17 Years 0.40-1.90 g/24 h > 17 Years 0.50-2.15 g/24 h |
Clinical Significance
NTx is useful to assess bone resorption in patients with metabolic bone disease and monitor therapy to slow or halt osteoporotic bone loss. A decline of 30% or more of NTx over a six-month period suggests effective therapy.
Performing Laboratory
Quest Diagnostics
